Cargando…

Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis

OBJECTIVE: Postmenopausal osteoporosis (PMOP) is one of the most commonly occurring conditions worldwide and is characterized by estrogen deficiency as well as persistent calcium loss with age. The aim of our study was to identify significant ferroptosis-associated biomarkers for PMOP. METHODS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yunxiang, Han, Jun, Ding, Shengqiang, Liu, Sanmao, Wang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464919/
https://www.ncbi.nlm.nih.gov/pubmed/36105394
http://dx.doi.org/10.3389/fendo.2022.986384
_version_ 1784787677954965504
author Hu, Yunxiang
Han, Jun
Ding, Shengqiang
Liu, Sanmao
Wang, Hong
author_facet Hu, Yunxiang
Han, Jun
Ding, Shengqiang
Liu, Sanmao
Wang, Hong
author_sort Hu, Yunxiang
collection PubMed
description OBJECTIVE: Postmenopausal osteoporosis (PMOP) is one of the most commonly occurring conditions worldwide and is characterized by estrogen deficiency as well as persistent calcium loss with age. The aim of our study was to identify significant ferroptosis-associated biomarkers for PMOP. METHODS AND MATERIALS: We obtained our training dataset from the Gene Expression Omnibus (GEO) database using GSE56815 expression profiling data. Meanwhile, we extracted ferroptosis-associated genes for further analysis. Differentially expressed ferroptosis-associated genes (DEFAGs) between OP patients and normal controls were selected using the “limma” package. We established a ferroptosis-associated gene signature using training models, specifically, random forest (RF) and support vector machine (SVM) models. It was further validated in another dataset (GSE56814) which also showed a high AUC: 0.98, indicating high diagnostic value. Using consensus clustering, the OP patient subtypes were identified. A ferroptosis associated gene (FAG)-Scoring scheme was developed by PCA. The important candidate genes associated with OP were also compared between different ferrclusters and geneclusters. RESULTS: There were significant DEFAGs acquired, of which five (HMOX1, HAMP, LPIN1, MAP3K5, FLT3) were selected for establishing a ferroptosis-associated gene signature. Analyzed from the ROC curve, our established RF model had a higher AUC value than the SVM model (RF model AUC:1.00). Considering these results, the established RF model was chosen to be the most appropriate training model. Later, based on the expression levels of the five DEFAGs, a clinical application nomogram was established. The OP patients were divided into two subtypes (ferrcluster A, B and genecluster A, B, respectively) according to the consensus clustering method based on DEFAGs and differentially expressed genes (DEGs). Ferrcluster B and genecluster B had higher ferroptosis score than ferrcluster A and genecluster A, respectively. The expression of COL1A1 gene was significantly higher in ferrcluster B and gencluster B compared with ferrcluster A and gencluster A, respectively, while there is no statistical difference in term of VDR gene, COL1A2 genes, and PTH gene expressions between ferrcluster A and B, together with gencluster A and B. CONCLUSIONS: On the basis of five explanatory variables (HMOX1, HAMP, LPIN1, MAP3K5 and FLT3), we developed a diagnostic ferroptosis-associated gene signature and identified two differently categorized OP subtypes that may potentially be applied for the early diagnosis and individualized treatment of PMOP. The ER gene, VDR gene, IL-6 gene, COL1A1 and COL1A2 genes, and PTH gene are important candidate gene of OP, however, more studies are still anticipated to further elucidate the relationship between these genes and ferroptosis in OP.
format Online
Article
Text
id pubmed-9464919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94649192022-09-13 Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis Hu, Yunxiang Han, Jun Ding, Shengqiang Liu, Sanmao Wang, Hong Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: Postmenopausal osteoporosis (PMOP) is one of the most commonly occurring conditions worldwide and is characterized by estrogen deficiency as well as persistent calcium loss with age. The aim of our study was to identify significant ferroptosis-associated biomarkers for PMOP. METHODS AND MATERIALS: We obtained our training dataset from the Gene Expression Omnibus (GEO) database using GSE56815 expression profiling data. Meanwhile, we extracted ferroptosis-associated genes for further analysis. Differentially expressed ferroptosis-associated genes (DEFAGs) between OP patients and normal controls were selected using the “limma” package. We established a ferroptosis-associated gene signature using training models, specifically, random forest (RF) and support vector machine (SVM) models. It was further validated in another dataset (GSE56814) which also showed a high AUC: 0.98, indicating high diagnostic value. Using consensus clustering, the OP patient subtypes were identified. A ferroptosis associated gene (FAG)-Scoring scheme was developed by PCA. The important candidate genes associated with OP were also compared between different ferrclusters and geneclusters. RESULTS: There were significant DEFAGs acquired, of which five (HMOX1, HAMP, LPIN1, MAP3K5, FLT3) were selected for establishing a ferroptosis-associated gene signature. Analyzed from the ROC curve, our established RF model had a higher AUC value than the SVM model (RF model AUC:1.00). Considering these results, the established RF model was chosen to be the most appropriate training model. Later, based on the expression levels of the five DEFAGs, a clinical application nomogram was established. The OP patients were divided into two subtypes (ferrcluster A, B and genecluster A, B, respectively) according to the consensus clustering method based on DEFAGs and differentially expressed genes (DEGs). Ferrcluster B and genecluster B had higher ferroptosis score than ferrcluster A and genecluster A, respectively. The expression of COL1A1 gene was significantly higher in ferrcluster B and gencluster B compared with ferrcluster A and gencluster A, respectively, while there is no statistical difference in term of VDR gene, COL1A2 genes, and PTH gene expressions between ferrcluster A and B, together with gencluster A and B. CONCLUSIONS: On the basis of five explanatory variables (HMOX1, HAMP, LPIN1, MAP3K5 and FLT3), we developed a diagnostic ferroptosis-associated gene signature and identified two differently categorized OP subtypes that may potentially be applied for the early diagnosis and individualized treatment of PMOP. The ER gene, VDR gene, IL-6 gene, COL1A1 and COL1A2 genes, and PTH gene are important candidate gene of OP, however, more studies are still anticipated to further elucidate the relationship between these genes and ferroptosis in OP. Frontiers Media S.A. 2022-08-29 /pmc/articles/PMC9464919/ /pubmed/36105394 http://dx.doi.org/10.3389/fendo.2022.986384 Text en Copyright © 2022 Hu, Han, Ding, Liu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Hu, Yunxiang
Han, Jun
Ding, Shengqiang
Liu, Sanmao
Wang, Hong
Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
title Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
title_full Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
title_fullStr Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
title_full_unstemmed Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
title_short Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
title_sort identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464919/
https://www.ncbi.nlm.nih.gov/pubmed/36105394
http://dx.doi.org/10.3389/fendo.2022.986384
work_keys_str_mv AT huyunxiang identificationofferroptosisassociatedbiomarkersforthepotentialdiagnosisandtreatmentofpostmenopausalosteoporosis
AT hanjun identificationofferroptosisassociatedbiomarkersforthepotentialdiagnosisandtreatmentofpostmenopausalosteoporosis
AT dingshengqiang identificationofferroptosisassociatedbiomarkersforthepotentialdiagnosisandtreatmentofpostmenopausalosteoporosis
AT liusanmao identificationofferroptosisassociatedbiomarkersforthepotentialdiagnosisandtreatmentofpostmenopausalosteoporosis
AT wanghong identificationofferroptosisassociatedbiomarkersforthepotentialdiagnosisandtreatmentofpostmenopausalosteoporosis